)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Elicio Therapeutics
Elicio Therapeutics (ELTX) investor relations material
Elicio Therapeutics KOL event summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOL event summary24 Jun, 2026
Introduction and agenda
The event focused on clinical and translational observations and the development path for ELI-002/ELI-002 7P in metastatic KRAS-mutated pancreatic ductal adenocarcinoma (PDAC), with presentations from expert oncologists and a live Q&A session.
The agenda included review of historical response rates, clinical case presentations, translational data, Phase 1 strategy, and plans for prospective studies.
KOL background and credentials
Presenters included Dr. Peter Hosein (Professor, University of Miami), Dr. Zev Wainberg (Professor, UCLA), and Dr. Christopher Haqq (EVP, Head of R&D, CMO).
Market insights and analysis
Complete and durable responses in metastatic PDAC are extremely rare, with historical CR rates of 0–8% across standard and experimental regimens.
Immunotherapy, particularly checkpoint inhibitors and combinations, has shown minimal efficacy in pancreatic cancer, with CR rates typically below 6%.
Rationale for combining ELI-002 with CPIs
Impact of ELI-002 on antigen spreading
AMPLIFY Metastatic trial lesion count criteria
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elicio Therapeutics
- Durable complete responses observed after ELI-002 7P and checkpoint inhibition in metastatic PDAC.ELTX
Corporate presentation29 Jun 2026 - ELI-002 7P delivers robust, durable immune responses in mKRAS cancers with strong clinical potential.ELTXCorporate presentation19 Jun 2026
- Post-hoc analysis shows ELI-002 7P improves DFS in RO resected patients, informing Phase 3 plans.ELTXStudy update16 Jun 2026
- ELI-002 immunotherapy shows strong immune response and survival benefit; phase II readout due mid-2026.ELTXBank of America Global Healthcare Conference 202614 May 2026
- Net loss of $11.8M, $14.9M cash, and $13M raised highlight urgent need for new funding by Q4 2026.ELTXQ1 202611 May 2026
- Reduced net loss, strong cash position, and key clinical milestones expected in 2026.ELTXQ4 202513 Mar 2026
- Biotech seeks $400M for cancer immunotherapy pipeline, with ongoing trials and going concern risk.ELTXRegistration Filing12 Mar 2026
- Phase II data for a lymph node-targeted KRAS immunotherapy show robust T cell responses and safety.ELTXTD Cowen 46th Annual Health Care Conference4 Mar 2026
- Shelf registration allows ongoing securities offerings with robust governance protections.ELTXRegistration Filing2 Mar 2026
Next Elicio Therapeutics earnings date
Q2 20267 Aug, 2026
Elicio Therapeutics
Next Elicio Therapeutics earnings date
Q2 20267 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage